Key result
Higher macular vessel density, peripheral non-perfusion, and elevated LDL predict aflibercept response in diabetic macular edema.
Observational (n=76)
Masked image grading
No
Answers are grounded in this paper and cite their sources.
Prospective study shows retinal angiographic biomarkers and high LDL predict aflibercept response in diabetic macular edema, suggesting utility in selecting optimal candidates.
This prospective single-center study aims to identify biomarkers that predict improvement in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at 6 months, in 76 eyes with diabetic macular edema (DME) treated monthly with intravitreal aflibercept. At baseline, all patients underwent standardized imaging with color photography, optical coherence tomography (OCT), fluorescein angiography (FA) and OCT angiography (OCTA). Glycosylated hemoglobin, renal function, dyslipidemia, hypertension, cardiovascular disease and smoking were recorded. Retinal images were graded in a masked fashion. Baseline imaging, systemic and demographic variables were investigated to detect associations to BCVA and CRT change post aflibercept. Predictors of BCVA improvement included greater macular vessel density quantified using OCTA (p = 0.001) and low-density lipoprotein (LDL) ≥ 2.6 mmol/L (p = 0.017). Lower macular vessel density eyes showed a significant reduction in CRT but no BCVA improvement. Predictors of CRT reduction included peripheral non-perfusion seen on ultrawide-field FA (p = 0.005) and LDL ≥ 2.6 mmol/L (p < 0.001). Retinal angiographic biomarkers derived from OCTA and ultrawide-field FA may help predict functional and anatomic response to anti-vascular endothelial growth factor (VEGF) therapy in patients with DME. Elevated LDL is associated with treatment response in DME. These results may be used to better-select patients who will benefit from intravitreal aflibercept for treatment of DME.
No takes yet. Share an insight, caveat, or question.
Hein et al. (2023) conducted an observational in Diabetic macular edema (DME) (n=76). Baseline angiographic and systemic biomarkers (macular vessel density on OCTA, peripheral non-perfusion on ultrawide-field FA, LDL ≥ 2.6 mmol/L) in patients receiving intravitreal aflibercept vs. Lower macular vessel density, absence of peripheral non-perfusion, or LDL < 2.6 mmol/L was evaluated on Improvement in best-corrected visual acuity (BCVA) and reduction in central retinal thickness (CRT) at 6 months (p=0.001). Greater macular vessel density on OCTA, peripheral non-perfusion on FA, and LDL ≥2.6 mmol/L predicted BCVA and CRT response to aflibercept in DME at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: